To be taught extra, the researchers investigated the post-vaccination antibody responses of Pfizer/BioNTech and CoronaVac vaccines in 124 adults (common age 42 to 63 years) with extreme weight problems who visited Obesity Center at Istanbul University-Cerrahpasa, Cerrahpaşa Medical College Hospitals, between August and November 2021. They additionally recruited a management group of 166 normal-weight adults (BMI lower than 25 kg/m2, common age 39 to 47 years) attending the Cerrahpasa Hospitals Vaccination Unit.
The researchers measured antibody ranges in blood samples taken from sufferers and regular weight controls who had acquired two doses of the Pfizer/BioNTech or CoronaVac vaccine and had acquired their second dose 4 weeks earlier. The contributors have been categorized by an infection historical past, whether or not or not they beforehand had COVID-19 (confirmed by their antibody profile).
Results of the Study
Overall, 130 contributors acquired two doses of Pfizer/BioNTech and 160 contributors two doses of CoronaVac, of whom 70 had prior SARS-CoV-2 an infection.
In these with out prior SARS-CoV-2 an infection and vaccinated with Pfizer/BioNTech, severely overweight sufferers had antibody ranges greater than thrice decrease than normal-weight controls (imply 5,823 vs. 19,371 AU/mL).
Similarly, in contributors with out prior SARS-CoV-2 an infection and vaccinated with CoronaVac, severely overweight sufferers had 27-fold decrease antibody ranges than normal-weight controls (imply 178 vs. 4,894 AU/mL).
However, in these with prior SARS-CoV-2 an infection, antibody ranges in severely overweight sufferers vaccinated with Pfizer/BioNTech or CoronaVac weren’t considerably completely different from normal-weight controls (imply 39,043 vs 14,115 AU/mL and three,221 vs 7,060 AU/ml, respectively).
Interestingly, the analyzes discovered that in severely overweight sufferers, with and with out prior SARS-CoV-2 an infection, antibody ranges in these vaccinated with Pfizer/BioNTech have been considerably greater than these vaccinated with CoronaVac.
“These results provide new information on the antibody response to SARS-CoV-2 vaccines in people with severe obesity and reinforce the importance of prioritising and increasing vaccine uptake in this vulnerable group,” says Prof. Yumuk. “Our study confirms that immune memory induced by prior infection alters the way in which people respond to vaccination and indicates that two doses of Pfizer/BioNTech vaccine may generate significantly more antibodies than CoronaVac in people with severe obesity, regardless of infection history. However, further research is needed to determine whether these higher antibody levels provide greater protection against COVID-19.”